PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18723475-0	2008	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.	Erlotinib Hydrochloride	80-103	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	53-58	
26359257-9	2015	CONCLUSION: ABCG2, ABCB1, and possibly other transporters influence in vivo disposition of (11)C-erlotinib and thereby affect its distribution to normal and potentially also tumor tissue.	Erlotinib Hydrochloride	91-106	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	19-24	
26359257-11	2015	The inhibition of ABCB1 and ABCG2 is a promising approach to enhance brain distribution of erlotinib to increase its efficacy in the treatment of brain tumors.	Erlotinib Hydrochloride	91-100	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	18-23	
20304939-0	2010	Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.	Erlotinib Hydrochloride	165-174	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	60-65	
18723475-0	2008	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.	Erlotinib Hydrochloride	105-112	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	53-58	
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	175-184	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-28	
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	84-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	23-28	
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	84-93	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	148-153	
33081568-0	2021	Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib.	Erlotinib Hydrochloride	175-184	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	148-153	
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	Erlotinib Hydrochloride	15-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89	
33081568-4	2021	co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET.	Erlotinib Hydrochloride	111-120	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	84-89	
33081568-9	2021	Co-infusion of erlotinib/tariquidar may potentially allow for complete ABCB1/ABCG2 inhibition at the BBB, while simultaneously achieving brain-targeted EGFR inhibition.	Erlotinib Hydrochloride	15-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	71-76	
29175983-14	2018	Conclusion: When Abcb1 and Abcg2 were disrupted in mice, brain uptake of 11C-erlotinib increased both at a tracer dose and at a pharmacologic dose.	Erlotinib Hydrochloride	73-86	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	17-22	
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Erlotinib Hydrochloride	149-158	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19	
30694684-0	2019	Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib.	Erlotinib Hydrochloride	149-158	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	122-127	
30415015-2	2018	Inhibition of ABCB1 and ABCG2 at the mouse BBB improved the BBB permeation of erlotinib but could not be achieved in humans.	Erlotinib Hydrochloride	78-87	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	14-19